CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Lexaria (LEXX) hopes FDA approval will ‘balloon’ market cap

By Kevin Donovan

20:58, 10 December 2021

Gloved hand adjusting a microscope over a slide
Lexaria hopes FDA approval sends stock higher - Photo: Shutterstock

Following Lexaria Bioscience’s discovery that its cannabidiol (CBD) delivery method had broader applications than initially thought, which sent the stock 20% higher, the company expects big things in the coming year to 18 months.

“Our market capitalisation doesn’t reflect what we’re doing,” said Lexaria’s head of Investor Relations George Jurčić. “We should see our market cap balloon over the next 18 months.”

Opening Friday at $4.88, down 17.5% from Wednesday’s $5.92 per-share high following the hypertension study results, Lexaria stock stands to rise significantly should the US Food and Drug Administration (FDA) approve its patented HydraTECH pharmaceutical delivery method for medical use.

“We don’t develop or manufacture pharmaceuticals. We partner with existing biopharmaceutical companies to license our technology."

FDA application

“We plan on taking the DehydraTECH process to the FDA in order to take it to the market,” Jurčić said. “The FDA is the highest bar to get over. After FDA approval it becomes basically a review process in other jurisdictions.”

DehydraTECH is designed to improve the efficacy of orally administered bioactive molecules, including anti-virals, vitamins, non-steroidal anti-inflammatory drugs, as well as cannabinoids and nicotine. Lexaria claims DehydraTECH increases a drug’s absorption into the body, reduces onset time to minutes, reduces side effects and masks unpleasant tastes, negating the need for artificial flavour enhancement.

Registered as a corporation in Nevada but based primarily in Kelowna, British Columbia, Canada, Lexaria is currently working with an undisclosed third-party advisor to present its case to the FDA. Lexaria expects to name the advisor in January.

DehydraTECH flow chartLexaria's process and benefits for DehydraTECH - Photo: Lexaria Biosciences

Canadian Research Council approval

In July, the Canadian Research Council certified that Lexaria’s DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity and that each drug tested remained stable and did not undergo any change in chemical structure.

“We don’t develop or manufacture pharmaceuticals. We partner with existing biopharmaceutical companies to license our technology,” Jurčić added. “The DehydraTECH process doesn’t alter a drug’s chemical composition.”

“The end goal is for the body to absorb medication quicker, to act as an accelerator,” Jurčić noted.


16,184.80 Price
+0.460% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Oil - Crude

71.33 Price
-0.140% 1D Chg, %
Long position overnight fee -0.0213%
Short position overnight fee -0.0006%
Overnight fee time 22:00 (UTC)
Spread 0.030


1,983.69 Price
-1.100% 1D Chg, %
Long position overnight fee -0.0199%
Short position overnight fee 0.0117%
Overnight fee time 22:00 (UTC)
Spread 0.30


41,899.90 Price
-4.360% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

2021 revenue doubled

While Lexaria lost roughly $5.69m for the year ended 31 August, its $722,738 annual revenue doubled the $384,543 full-year 2020 revenue, the company reported last month. The majority of Lexaria’s revenue – $383,179, or 53% – derives from licensing its orally delivered hemp CBD technology.

Lexaria currently has $11m cash on hand and is fully funded through mid-2023. “We shouldn’t have any need to raise additional capital through the second or third quarter of 2023,” Jurčić said.

Jurčić believes that with FDA approval, “someone will knock on our door” to license its technology for various pharmaceutical medications.

Future plans

Currently focussed on its Hemp CBD delivery process for hypertension, as well as nicotine cessation, Lexaria has also turned its focus on Covid-19. “We’ve worked on a Covid-19 delivery product,” Jurčić added, citing Merck’s development of a Covid-19 pill.

In the future, Lexaria plans to expand the application of its DehydraTECH delivery method to Alzheimer’s disease, diabetes and epilepsy drugs.

The DehydraTECH delivery method can theoretically be applied to a wide variety of pharmaceutical treatments. “The initial goal of the (HYPER-H21-H) CBD trial was to lower blood pressure and we noticed it also softened arteries.”

“That really just fell out of the sky.”

Read more: Lexaria (LEXX) stock jumps 24% on positive CBD test results

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading